Latest News in the pharma Industry

Research & Development

Biogen completes rolling submission of NDA to FDA for nusinersen as a treatment for spinal muscular atrophy

Biogen completes rolling submission of NDA to FDA for nusinersen as a treatment for spinal muscular atrophy

27 Sep 2016

Submission of Marketing Authorization Application to the EMA planned in the coming weeks.

Read more 
BARDA Grants $43.2 million USD to Sanofi Pasteur for Zika

BARDA Grants $43.2 million USD to Sanofi Pasteur for Zika

26 Sep 2016

Funds will be used for Phase II development and manufacturing.

Read more 
Novartis receives three new FDA approvals for the expanded use of Ilaris

Novartis receives three new FDA approvals for the expanded use of Ilaris

23 Sep 2016

Ilaris is the first and only US FDA-approved biologic treatment for patients with TRAPS, HIDS/MKD and FMF disease.

Read more 
To produce biopharmaceuticals on demand, just add water

To produce biopharmaceuticals on demand, just add water

22 Sep 2016

Freeze-dried cellular components can be rehydrated to churn out useful proteins.

Read more 
Novel Novartis malaria compound shows potential to be effective against infections resistant to all currently available antimalarial drugs

Novel Novartis malaria compound shows potential to be effective against infections resistant to all currently available antimalarial drugs

22 Sep 2016

Results published in the New England Journal of Medicine demonstrate that KAF156 shows activity against blood and liver stages of malaria parasites, including artemisinin-resistant parasites.

Read more 
EMA validates BMS’s type II variation application for Opdivo in advanced form of bladder cancer

EMA validates BMS’s type II variation application for Opdivo in advanced form of bladder cancer

20 Sep 2016

Extends the current indications for Opdivo to include the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy.

Read more 
Optibrium and The Edge collaborate to integrate StarDrop with BioRails platforms

Optibrium and The Edge collaborate to integrate StarDrop with BioRails platforms

20 Sep 2016

Combination provides an enterprise platform for comprehensive data management, analysis and compound design in drug discovery.

Read more 
Heparan sulfate antibodies applications guide

Heparan sulfate antibodies applications guide

20 Sep 2016

New 24-page guide that brings together applications, protocols, results and citations for researchers.

Read more 
Gene therapy technique may help prevent cancer metastasis

Gene therapy technique may help prevent cancer metastasis

19 Sep 2016

Gene-regulating RNA molecules could help treat early-stage breast cancer tumours before they spread.

Read more 
Osteoarthritis space set to undergo radical changes, approaching $10.5 billion by 2024

Osteoarthritis space set to undergo radical changes, approaching $10.5 billion by 2024

19 Sep 2016

Current R&D strategies in osteoarthritis are characterized by a trend towards developing new analgesics with novel MOAs, and drugs with disease-modifying effects.

Read more 
FDA grants accelerated approval to first drug for Duchenne muscular dystrophy

FDA grants accelerated approval to first drug for Duchenne muscular dystrophy

19 Sep 2016

Approval given to EXONDYS 51 (eteplirsen) as a once weekly intravenous infusion of 30 mg/kg for the treatment of DMD in patients who have a confirmed mutation in the DMD gene that is amenable to exon 51 skipping.

Read more 
Phase III combination trial of Bydureon and Farxiga shows significant blood sugar reduction in patients with type 2 diabetes

Phase III combination trial of Bydureon and Farxiga shows significant blood sugar reduction in patients with type 2 diabetes

18 Sep 2016

This was the first clinical trial to combine these two different anti-diabetes medicines, a GLP-1 receptor agonist and an SGLT-2 inhibitor, as an addition to standard-of-care therapy to evaluate potential benefits for patients with type 2 diabetes with...

Read more